Latest news with #vMap
Business Wire
23-04-2025
- Health
- Business Wire
Vektor Medical Announces Post-Market Study Evaluating Benefit of AI-Powered Analysis to Identify and Ablate Non-Pulmonary Vein AF Targets
SAN DIEGO--(BUSINESS WIRE)-- Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced the initiation of the IMPRoVED AF clinical study designed to evaluate the benefit of utilizing AI-driven mapping to identify and ablate non-pulmonary vein electrical drivers implicated in persistent and recurrent atrial fibrillation (AF). "The IMPRoVED-AF trial represents a landmark moment for Vektor, validating vMap's clinical efficacy and demonstrating our ability to dramatically improve outcomes and redefine arrhythmia care." Rob Krummen, CEO, Vektor Medical IMPRoVED AF (artificial Intelligence Mapping and ablation of non-PulmonaRy Vein Electrical Drivers of AF) is a prospective, randomized, controlled, multi-center study clinical trial that will rigorously compare clinical outcomes in patients undergoing pulmonary vein isolation (PVI) alone versus PVI and additional driver ablation guided by Vektor's proprietary vMap technology. vMap is the only FDA-cleared non-invasive AI-powered arrhythmia analysis technology designed to improve, enhance, and accelerate ablation procedures, utilizing data from a standard 12-lead ECG. 'Persistent and recurrent AF remains incredibly challenging, profoundly affecting patient quality of life and burdening our healthcare systems,' said Dr. Gery Tomassoni, Principal Investigator and cardiac electrophysiologist at Baptist Health Lexington. 'The IMPRoVED AF study is positioned to address this challenge. By leveraging AI-driven technology, we aim to significantly enhance ablation accuracy and effectiveness, potentially redefining the standard for managing persistent AF.' The study, managed by clinical research organization Veranex, will enroll up to 384 patients with persistent (not longstanding) and recurrent AF at 15 electrophysiology centers across the United States and Europe. The study's design specifically aims to demonstrate the comparative clinical benefit of utilizing AI-driven mapping to identify and ablate non-pulmonary vein electrical hotspots in accordance with standard-of-care ablation practices. The primary endpoint of the study is freedom from AF on or off antiarrhythmic drugs at 12 months. Additional secondary endpoints include: freedom from AF and atrial tachycardia on and off antiarrhythmic drugs at 12 months total procedure time total vMap mapping time AF burden as a proportion of time before versus after ablation proportion of subjects with AF terminated spontaneously upon and after the first ablation, and total fluoroscopy dose. Interim results are anticipated by HRS 2026; comprehensive results are expected at HRS 2027. 'EPs can't ablate what they can't identify. That's exactly why vMap was created - to empower EPs with actionable insights previously inaccessible from a standard ECG,' said Rob Krummen, CEO of Vektor Medical. 'The IMPRoVED AF trial represents a landmark moment for Vektor, validating vMap's clinical efficacy and demonstrating our ability to dramatically improve outcomes and redefine arrhythmia care. Re-do procedures have unfortunately become the norm, underscoring the critical need for technologies that provide additional insight on arrhythmia sources.' In parallel with the IMPRoVED AF study, Vektor has also initiated the VITAL-EP registry to collect real-world data on the clinical utility, safety, and procedural efficiency of vMap-guided ablation procedures. The registry, managed by clinical research organization Heart Rhythm Clinical and Research Solutions, aims to enroll at least 110 patients across four sites. The registry will evaluate multiple procedural-related endpoints, including AF termination or AF non-inducibility in AF ablation cases and procedure efficiency, including procedure duration and fluoroscopy use. About vMap ® vMap is the only FDA-cleared, non-invasive AI-based solution for mapping arrhythmias, utilizing just a 12-lead ECG. vMap localizes arrhythmia sources for focal and fibrillation-type arrhythmias, including atrial fibrillation. By unlocking actionable insights contained within a standard 12-lead ECG, vMap enables physicians to rapidly and accurately locate arrhythmia source locations. Backed by extensive clinical evidence, vMap not only improves patient outcomes but also reduces procedure time, optimizing workflow across the entire arrhythmia care pathway. About Vektor Medical Headquartered in San Diego, Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-powered, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. For more information about vMap and Vektor Medical, please visit Connect with Vektor Medical on LinkedIn and X.
Yahoo
23-04-2025
- Health
- Yahoo
Vektor Medical Announces Post-Market Study Evaluating Benefit of AI-Powered Analysis to Identify and Ablate Non-Pulmonary Vein AF Targets
IMPRoVED AF RCT and VITAL-EP Registry Reinforce Vektor's Focus on Data That Drives EP Adoption and Ablation Outcomes SAN DIEGO, April 23, 2025--(BUSINESS WIRE)--Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced the initiation of the IMPRoVED AF clinical study designed to evaluate the benefit of utilizing AI-driven mapping to identify and ablate non-pulmonary vein electrical drivers implicated in persistent and recurrent atrial fibrillation (AF). IMPRoVED AF (artificial Intelligence Mapping and ablation of non-PulmonaRy Vein Electrical Drivers of AF) is a prospective, randomized, controlled, multi-center study clinical trial that will rigorously compare clinical outcomes in patients undergoing pulmonary vein isolation (PVI) alone versus PVI and additional driver ablation guided by Vektor's proprietary vMap technology. vMap is the only FDA-cleared non-invasive AI-powered arrhythmia analysis technology designed to improve, enhance, and accelerate ablation procedures, utilizing data from a standard 12-lead ECG. "Persistent and recurrent AF remains incredibly challenging, profoundly affecting patient quality of life and burdening our healthcare systems," said Dr. Gery Tomassoni, Principal Investigator and cardiac electrophysiologist at Baptist Health Lexington. "The IMPRoVED AF study is positioned to address this challenge. By leveraging AI-driven technology, we aim to significantly enhance ablation accuracy and effectiveness, potentially redefining the standard for managing persistent AF." The study, managed by clinical research organization Veranex, will enroll up to 384 patients with persistent (not longstanding) and recurrent AF at 15 electrophysiology centers across the United States and Europe. The study's design specifically aims to demonstrate the comparative clinical benefit of utilizing AI-driven mapping to identify and ablate non-pulmonary vein electrical hotspots in accordance with standard-of-care ablation practices. The primary endpoint of the study is freedom from AF on or off antiarrhythmic drugs at 12 months. Additional secondary endpoints include: freedom from AF and atrial tachycardia on and off antiarrhythmic drugs at 12 months total procedure time total vMap mapping time AF burden as a proportion of time before versus after ablation proportion of subjects with AF terminated spontaneously upon and after the first ablation, and total fluoroscopy dose. Interim results are anticipated by HRS 2026; comprehensive results are expected at HRS 2027. "EPs can't ablate what they can't identify. That's exactly why vMap was created - to empower EPs with actionable insights previously inaccessible from a standard ECG," said Rob Krummen, CEO of Vektor Medical. "The IMPRoVED AF trial represents a landmark moment for Vektor, validating vMap's clinical efficacy and demonstrating our ability to dramatically improve outcomes and redefine arrhythmia care. Re-do procedures have unfortunately become the norm, underscoring the critical need for technologies that provide additional insight on arrhythmia sources." In parallel with the IMPRoVED AF study, Vektor has also initiated the VITAL-EP registry to collect real-world data on the clinical utility, safety, and procedural efficiency of vMap-guided ablation procedures. The registry, managed by clinical research organization Heart Rhythm Clinical and Research Solutions, aims to enroll at least 110 patients across four sites. The registry will evaluate multiple procedural-related endpoints, including AF termination or AF non-inducibility in AF ablation cases and procedure efficiency, including procedure duration and fluoroscopy use. About vMap® vMap is the only FDA-cleared, non-invasive AI-based solution for mapping arrhythmias, utilizing just a 12-lead ECG. vMap localizes arrhythmia sources for focal and fibrillation-type arrhythmias, including atrial fibrillation. By unlocking actionable insights contained within a standard 12-lead ECG, vMap enables physicians to rapidly and accurately locate arrhythmia source locations. Backed by extensive clinical evidence, vMap not only improves patient outcomes but also reduces procedure time, optimizing workflow across the entire arrhythmia care pathway. About Vektor Medical Headquartered in San Diego, Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-powered, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. For more information about vMap and Vektor Medical, please visit Connect with Vektor Medical on LinkedIn and X. View source version on Contacts Media Contact Stacey HolifieldLevitate(617) 233-3873vektor@
Business Wire
21-04-2025
- Health
- Business Wire
The Future of AI & Electrophysiology Takes Center Stage at Heart Rhythm 2025 with Vektor Medical
SAN DIEGO--(BUSINESS WIRE)-- Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, will showcase its transformative vMap technology at Heart Rhythm 2025, taking place April 25–27 in San Diego. Through live demonstrations at adjacent booths (#1523 and #1622), scientific abstract presentations, and a highly anticipated Rhythm Theater session featuring leading electrophysiologists, Vektor will offer attendees a firsthand look at how vMap is being integrated into clinical workflows to support more informed, efficient, and effective ablation strategies. This unique, data-driven approach is helping EPs accelerate diagnosis, enhance procedural accuracy, and improve outcomes across the arrhythmia care spectrum. Share vMap is the only FDA-cleared, AI-based arrhythmia analysis solution that uses a standard 12-lead ECG to non-invasively localize arrhythmia sources, including both focal and fibrillation-type rhythms. This unique, data-driven approach is helping EPs accelerate diagnosis, enhance procedural accuracy, and improve outcomes across the arrhythmia care spectrum. Experience vMap in Action Visit Booths #1523 and #1622 (side-by-side) to explore how vMap is redefining arrhythmia source localization. See firsthand how physicians use the technology to improve outcomes, streamline workflows, and expand access to effective treatment. Schedule a one-on-one demo with the Vektor team here. Rhythm Theater Session 'AI and PFA: A Complementary Approach to Arrhythmia Treatment' Saturday, April 26 | 9:15 – 10:00 a.m. | Rhythm Theater 2 Moderated by Dr. Devi Nair, Director of Cardiac Electrophysiology at St. Bernards Heart & Vascular, this session will spotlight how AI-powered ECG analysis elevates the standard of care in EP labs. The panel will also explore how vMap integrates with pulsed field ablation (PFA) and other advanced treatment strategies. Panelists and discussion topics include: Dr. Gery Tomassoni, Baptist Health Lexington: Non-PV Driver Ablation with vMap and Upcoming Clinical Studies Dr. Benjamin D'Souza, Penn Medicine: vMap's Role in VT Ablation and Procedural Outcomes Dr. Anish Amin, OhioHealth: Integrating vMap into AF Ablation Procedures with PFA Scientific Abstract Presentations Mapping of Unstable Scar Mediated Ventricular Tachycardias: A Novel Technique Saturday, April 26 | 9:30 – 11:30 a.m. Dr. Faris Haddadin Abstract Pavilion Optimizing Procedural Techniques for Improved Ablation Outcomes Sunday, April 27 | 8:00 – 9:00 a.m. 'Prospective Non-Invasive Artificial Intelligence-Based CT and ECG Localization of Scar-Based Ventricular Arrhythmias' - Dr. Gordon Ho Oral Abstract Hub 1 – Sails Pavilion 'vMap addresses a critical gap in arrhythmia care,' said Rob Krummen, CEO of Vektor Medical. 'Electrophysiologists across the U.S. are using vMap to guide ablation strategies with greater confidence, and the results are gaining attention. At HRS, we are proud to showcase that impact through live demos and by amplifying the voices of the physicians using this technology every day. As we prepare to launch multiple key clinical studies, including our pivotal randomized trial, we are deepening the clinical foundation for broader adoption. This is a pivotal moment—for Vektor and the future of electrophysiology.' About vMap® vMap is the only FDA-cleared, non-invasive AI-powered solution for mapping arrhythmias, utilizing just a 12-lead ECG. vMap localizes arrhythmia sources for focal and fibrillatory arrhythmias, including atrial fibrillation. By unlocking actionable insights contained within a standard 12-lead ECG, vMap enables physicians to rapidly and accurately locate arrhythmia source locations. Backed by extensive clinical evidence, vMap not only improves patient outcomes but also reduces procedure time, optimizing workflow across the entire arrhythmia care pathway. About Vektor Medical Headquartered in San Diego, Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-powered, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. For more information about vMap and Vektor Medical, please visit Connect with Vektor Medical on LinkedIn and X.
Yahoo
03-04-2025
- Health
- Yahoo
CORRECTING and REPLACING Heart Rhythm Case Reports Publishes Notable Case Detailing First Use of AI-Guided ECG Mapping for Left Bundle Branch Area Pacing
Case Report Demonstrates How vMap Enhances Accuracy and Reduces Risk in Pacemaker Implantation SAN DIEGO, April 03, 2025--(BUSINESS WIRE)--In the release dated April 1, 2025, the quote from, and photo of, Dr. Ulrika Birgersdotter-Green has been removed. The updated release reads: HEART RHYTHM CASE REPORTS PUBLISHES NOTABLE CASE DETAILING FIRST USE OF AI-GUIDED ECG MAPPING FOR LEFT BUNDLE BRANCH AREA PACING Case Report Demonstrates How vMap Enhances Accuracy and Reduces Risk in Pacemaker Implantation Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced the publication of a groundbreaking case in Heart Rhythm Case Reports. Conducted by physicians from the University of California San Diego (UCSD), the case details the first successful use of AI-enabled ECG mapping to guide left bundle branch area pacing (LBBAP) implantation. Findings highlight how vMap, a non-invasive AI-powered mapping technology, enhances procedural efficiency, accuracy, and patient safety during LBBAP lead positioning. As LBBAP becomes a preferred physiologic pacing technique, vMap has the potential to offer a transformative approach by reducing fluoroscopy exposure and eliminating the need for contrast agents - critical factors in enhancing patient safety and procedural outcomes. The patient in the case report, a 90-year-old male with advanced chronic kidney disease and a severe iodinated contrast allergy, underwent a dual-chamber LBBAP implantation as physicians used vMap for peri-procedural AI-driven guidance. The procedure was completed successfully with minimized fluoroscopy time and without contrast injection, mitigating risks associated with traditional approaches for the patient and physician. Procedure Highlights: vMap provided peri-procedural, AI-driven guidance to position the lead accurately on the RV septum. vMap compared the patient's QRS morphology with a digital reference library of thousands of cardiac simulations of right ventricular pacing, helping localize the lead tip within the heart. Successful lead placement was achieved with confirmed left bundle capture, reducing reliance on traditional fluoroscopic imaging. vMap's ability to store and analyze paced QRS morphology enabled more efficient mapping, particularly in cases where the ideal pacing site was not immediately encountered. The case report underscores vMap's ability to transform cardiac pacing workflows while prioritizing patient safety. As the only FDA-cleared, non-invasive AI-based solution for mapping arrhythmias and analyzing atrial and ventricular pacing via a standard 12-lead ECG, vMap represents a significant advancement in electrophysiology. "This case is the first time vMap has been used to help guide LBBAP implantation. In addition to the positive procedural benefits, it's a very clear demonstration of the potential for vMap to more broadly improve cardiac care and advance various cardiac interventions," said Rob Krummen, CEO of Vektor Medical. For more information on Vektor Medical and vMap, visit and connect on LinkedIn and X. About Vektor Medical Headquartered in San Diego, Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-powered, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. For more information about vMap and Vektor Medical, please visit View source version on Contacts Media Contact Stacey HolifieldLevitate(617) 233-3873vektor@
Yahoo
17-03-2025
- Business
- Yahoo
Vektor Medical Strengthens Leadership Team to Accelerate Commercial Growth and Market Expansion
Corporate Update to be Presented at LSI USA SAN DIEGO, March 17, 2025--(BUSINESS WIRE)--Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced key leadership appointments to support commercial expansion and market entry initiatives. Michael Andersen has joined the company as Vice President, Sales, and Mihir Naik has been promoted to Vice President, Quality Assurance and Regulatory Affairs. These key moves position Vektor for rapid growth following its recently oversubscribed $25M Series A funding round. "The expansion of our leadership team comes at a pivotal moment as we advance commercialization and prepare to enter new markets; we must have the right leadership in place to execute our strategy," said Rob Krummen, CEO of Vektor Medical. "Mike brings the expertise and experience to continue to expand vMap adoption among electrophysiologists, while Mihir's leadership ensures we maintain the highest regulatory and quality standards as we grow. Their leadership is instrumental as we work to deliver on our mission to transform arrhythmia care. I look forward to sharing more about our progress and vision during my presentation at LSI this week." Michael Andersen, VP, Sales Michael Andersen brings more than 20 years of commercial leadership experience in electrophysiology and medtech, with a strong track record of market development, sales execution, and strategic growth. Previously, he held senior roles at Hillrom, Abbott, and St. Jude Medical, where he successfully launched and expanded sales of advanced electrophysiology solutions. His expertise will be key in driving the adoption of vMap and accelerating revenue growth as Vektor expands its market presence. Mihir Naik, VP, Quality Assurance and Regulatory Affairs Mihir Naik has been promoted to Vice President, Quality Assurance and Regulatory Affairs, reinforcing Vektor's unwavering commitment to patient safety, quality and regulatory excellence. Since joining the company, Mihir has played a key role in ensuring FDA compliance, a robust quality and compliance framework that supports commercial success while meeting global industry standards. Corporate Update at LSI USA CEO Rob Krummen will present a corporate update at LSI USA in Dana Point, California, on March 19 at 1:45 PM PST. The presentation will cover Vektor Medical's strengthened leadership, commercial momentum, and commitment to innovation - fueled by the $25M Series A funding round, led by TVM Biosciences and Solas Bioventures. It will also provide insights into our future strategies and plans for vMap adoption and market expansion. For more information on Vektor Medical and vMap, visit and connect on LinkedIn and X. About Vektor Medical Headquartered in San Diego, Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-powered, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. For more information about vMap and Vektor Medical, please visit View source version on Contacts Media Contact Stacey HolifieldLevitate(617) 233-3873vektor@ Sign in to access your portfolio
